Biodesix will present findings on lung nodule management at the 2025 CHEST Annual Meeting in Chicago, October 19-22.
Quiver AI Summary
Biodesix, Inc. will participate in the 2025 CHEST Annual Meeting from October 19-22 in Chicago, highlighting their diagnostic solutions for lung nodule management. Key presentations include an interim analysis of the CLARIFY study focused on the Nodify tests, with Dr. Michael Kammer presenting preliminary data on the first 1,000 enrolled patients. Additional presentations will cover healthcare resource utilization related to pulmonary nodules and the clinical value of the Nodify Lung tests in various patient populations. Biodesix executives will also be present at their booth to discuss advancements in lung health diagnostics. CEO Scott Hutton emphasized the significance of the event coinciding with Lung Cancer Awareness Month, marking an important moment for innovations in lung diagnostics.
Potential Positives
- Biodesix is presenting significant data from the CLARIFY study, which seeks to validate the performance of its Nodify CDT® and Nodify XL2® tests, indicating ongoing research and commitment to improving lung cancer diagnosis and treatment.
- The company's participation at the 2025 CHEST Annual Meeting reflects its dedication to educating healthcare professionals about its products, enhancing brand reputation and visibility within the medical community.
- Numerous independent presentations will highlight the clinical value of Biodesix's tests, showcasing their effectiveness in diverse real-world patient populations and potentially broadening acceptance and usage.
Potential Negatives
- The press release does not disclose any concrete results or findings from the CLARIFY study, which may raise concerns about the lack of transparency regarding the effectiveness of their tests.
- The presence of numerous independent presentations by healthcare professionals could imply that the necessity for external validation of Biodesix's tests may undermine the credibility of their own findings.
- Although promoting the upcoming presentations, the release does not address any potential criticisms or limitations of their studies, which could weaken investor confidence.
FAQ
What is Biodesix presenting at the 2025 CHEST Annual Meeting?
Biodesix will present data from the CLARIFY study focusing on lung nodule management and test performance analysis.
When and where is Biodesix's Learning Theater presentation?
The presentation will be on October 21 at 2:00 pm CDT in Learning Theater 4, Chicago, Illinois.
What tests are being discussed in the CLARIFY study?
The study reviews the performance of Nodify CDT® and Nodify XL2® tests in various patient subgroups.
Who is the presenting author for the healthcare resource utilization analysis?
Kimberly Le, PharmD, MS, MBA, will present on pulmonary nodule-related healthcare resource utilization on October 22.
What is the significance of Lung Cancer Awareness Month for Biodesix?
Lung Cancer Awareness Month begins on November 1, highlighting the importance of lung diagnostics in improving patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 21 times in the past 6 months. Of those trades, 6 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 6 purchases buying 8,372,029 shares for an estimated $3,928,046 and 0 sales.
- SCOTT HUTTON (President & CEO) has made 0 purchases and 3 sales selling 7,547 shares for an estimated $2,914.
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 3 sales selling 1,980 shares for an estimated $764.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 3 sales selling 953 shares for an estimated $368.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 3 sales selling 887 shares for an estimated $342.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 3 sales selling 452 shares for an estimated $174.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Hedge Fund Activity
We have seen 14 institutional investors add shares of $BDSX stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 4,272,591 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,205,725
- OPALEYE MANAGEMENT INC. removed 3,225,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $910,095
- SILVERARC CAPITAL MANAGEMENT, LLC removed 3,028,039 shares (-73.9%) from their portfolio in Q2 2025, for an estimated $854,512
- SAMJO MANAGEMENT, LLC removed 2,408,100 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $679,565
- MONASHEE INVESTMENT MANAGEMENT LLC removed 2,050,000 shares (-50.6%) from their portfolio in Q2 2025, for an estimated $578,510
- FARALLON CAPITAL MANAGEMENT LLC removed 1,731,308 shares (-93.1%) from their portfolio in Q2 2025, for an estimated $488,575
- GSA CAPITAL PARTNERS LLP added 898,059 shares (+2694.0%) to their portfolio in Q2 2025, for an estimated $253,432
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BDSX Analyst Ratings
Wall Street analysts have issued reports on $BDSX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Craig-Hallum issued a "Buy" rating on 05/14/2025
- Lake Street issued a "Buy" rating on 05/14/2025
- Canaccord Genuity issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $BDSX, check out Quiver Quantitative's $BDSX forecast page.
$BDSX Price Targets
Multiple analysts have issued price targets for $BDSX recently. We have seen 4 analysts offer price targets for $BDSX in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $20.0 on 09/19/2025
- Sung Ji Nam from Scotiabank set a target price of $2.0 on 05/21/2025
- Bill Bonello from Craig-Hallum set a target price of $1.5 on 05/14/2025
- Thomas Flaten from Lake Street set a target price of $2.0 on 05/14/2025
Full Release
LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois.
Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation.
Title
:
Driving to a New Standard of Care in Lung Nodule Management: Preliminary Results from the Nodify Lung Real-World CLARIFY Study
Presenter
: Michael Kammer, PhD, Head of Radiomics at Biodesix
Location
: Learning Theater 4
Date and Time
: Biodesix Learning Theatre, October 21 at 2:00 pm CDT
Description
: This presentation will review analysis from the first 1,000 patients enrolled in the CLARIFY study. The CLARIFY study began patient enrollment shortly after the 2024 CHEST Annual Meeting and is designed to confirm performance of the Nodify CDT
®
and Nodify XL2
®
tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients with at least 1-year follow-up since being tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of the Nodify Lung tests.
A national analysis of lung nodules receiving clinical work-up across diverse care settings will also be presented at the meeting, highlighting the need for more structured lung nodule management approaches to optimize efficiency of healthcare resource utilization and improve patient outcomes.
Title
:
Pulmonary Nodule-related Healthcare Resource Utilization After Diagnosis of Pulmonary Nodule in the United States
Presenting Author
: Kimberly Le, PharmD, MS, MBA, Director of Health Economics Outcomes Research at Biodesix
Date and Time
: Wednesday, October 22, 10:20 AM
It is important to note that there will be numerous independent presentations by healthcare professionals highlighting the clinical value of the Nodify Lung tests in their own real-world patient populations. Examples are below.
Title
: Comparison of the Blood-based Nodify XL2 Test with PET/CT to Evaluate for Malignancy in Indeterminate Pulmonary Nodules in an Endemic Fungal Region
Presenting Author
: Michael Torres Lizardi, MD
Date and Time
: Sunday, October 19, 11:20 AM CDT
Title
: Impact of the Nodify Lung Test Strategy in the Risk Stratification of Lung Nodules in Patients of a Pulmonary Practice in Miami
Presenting Author
: Elizabeth Samper Perez
Date and Time
: Wednesday, October 22, 10:20 AM CDT
Title
: The Association of Lung Cancer Screening (LCS) and Proteomic Lung Nodule Testing in an Unrepresentative Minority Community (UMC) in Brooklyn, NY
Presenting Author
: Juan Martinez Zegarra, MD
Date and Time
: Wednesday, October 22, 10:20 AM CDT
Title
: A Retrospective Analysis of Biodesix Biomarker to Assess Efficacy in Risk Stratification and Reduction of Invasive Surgical Procedures in Detected Solitary Pulmonary Nodules
Presenting Author
: Kevin Huynh, DO
Date and Time
: Wednesday, October 22, 10:20 AM CDT
In addition, Biodesix executive leaders and medical officers will be present at the Biodesix booth #1012 to discuss the future of biomarkers for lung nodule management and lung health diagnostics.
“It is an exciting time to be part of the lung diagnostics space, with biomarkers poised to transform and improve patient care,” said Scott Hutton, CEO at Biodesix. "With thousands of lung specialists coming together, the CHEST Annual Meeting offers a pivotal moment in lung diagnostics and in the fight against lung cancer. It’s great timing with Lung Cancer Awareness Month starting November 1 st .”
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , marketed as Nodify Lung ® Nodule Risk Assessment and IQLung ® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
[email protected]
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843
